Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS<sup>G12C</sup> with Demonstrable CNS Penetration-Reference-Cited by-同舟云学术

Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS^G12C with Demonstrable CNS Penetration

Published:2023-07-03 Issue:13 Volume:66 Page:9147-9160
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Kettle Jason G.¹^ORCID,Bagal Sharan K.¹,Barratt Derek²,Bodnarchuk Michael S.¹^ORCID,Boyd Scott¹,Braybrooke Erin¹,Breed Jason²,Cassar Doyle J.¹^ORCID,Cosulich Sabina¹,Davies Michael¹,Davies Nichola L.¹,Deng Chao³,Eatherton Andrew¹,Evans Laura¹,Feron Lyman J.¹,Fillery Shaun¹^ORCID,Gleave Emma S.²,Goldberg Frederick W.¹^ORCID,Cortés González Miguel A.⁴^ORCID,Guerot Carine¹,Haider Afreen²,Harlfinger Stephanie¹,Howells Rachel¹,Jackson Anne²,Johnström Peter⁵⁴,Kemmitt Paul D.¹,Koers Alex¹,Kondrashov Mikhail⁴,Lamont Gillian M.¹,Lamont Scott¹,Lewis Hilary J.¹^ORCID,Liu Libin³,Mylrea Megan¹,Nash Samuel¹,Niedbala Michael J.⁶,Peter Alison¹,Phillips Christopher²,Pike Kurt¹,Raubo Piotr¹,Robb Graeme R.¹^ORCID,Ross Sarah¹,Sanders Matthew G.¹,Schou Magnus⁵⁴^ORCID,Simpson Iain¹,Steward Oliver¹

Affiliation:

1. Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.

2. Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K.

3. Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA, Beijing 100176, P. R. China

4. Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden

5. PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm SE-171 76, Sweden

6. Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00746

Reference43 articles.

1. The Frequency of Ras Mutations in Cancer

2. Targeting RAS signalling pathways in cancer therapy

3. Direct inhibition of RAS: Quest for the Holy Grail?